IVD China this week: Mindray, Getein Biotech and Hotgen Biotech

Mindray's revenue exceeded CNY18.4 billion in the first half of the year, with significant growth in its in vitro diagnostic business

On August 30th, Mindray disclosed its semiannual report. In the first half of this year, the company achieved a revenue of CNY18.476 billion, a year-on-year increase of 20.32%; The net profit attributable to the parent company was CNY6.442 billion, a year-on-year increase of 21.83%.

From the business perspective, the company's life information and support business achieved a revenue of CNY8.667 billion, a year-on-year increase of 27.99%; The in vitro diagnosis business achieved a revenue of CNY5.975 billion, a year-on-year increase of 16.18%, while the medical imaging business achieved a revenue of CNY3.701 billion, a year-on-year increase of 13.40%. Among them, the in vitro diagnosis and medical imaging businesses both grew by over 35% in the second quarter.

Getein Biotech's regular business grew in the first half of the year, with stable chemiluminescence business continuously breakthrough

Recently, Getein Biotech disclosed its 2023 semiannual report. In the first half of the year, the company achieved operating revenue of CNY703 million, net profit attributable to the parent company of CNY169 million, and total assets of CNY3.678 billion. 

In the first half of the year, Getein Biotech continued to focus on conventional business, fully exploring the market, fully leveraging its advantages such as independent research and development innovation and the layout of the entire IVD product line. While maintaining its leading position in the POCT market, it achieved steady growth in revenue from conventional business through continuous research and development investment and product innovation, and steadily advanced towards the strategic goal of building the brand in all aspects.

Hotgen achieved a net profit of CNY84.7687 million in the first half of the year and achieved rapid growth in routine clinical business

On the evening of August 29th, Hotgen disclosed its 2023 semiannual report. The company achieved a revenue of CNY307 million in the first half of the year, a net profit of CNY84.7687 million, a deduction of 52.7228 million yuan from non-net profit, and a basic earnings per share of 0.95 yuan.

Hotgen continues to increase research and development investment. As of the end of the reporting period, the company has invested a total of CNY68.1175 million in research and development, accounting for 22.19% of revenue, an increase of 18.19% year-on-year.